Study Identifies First Case of Spontaneous Genetic Correction in Severe Immunodeficiency
A study has identified, for the first time, a case of spontaneous correction of a genetic mutation in a patient with CD137 deficiency, a rare immunodeficiency that causes vulnerability to Epstein–Barr virus infection.
GAMMAGARD LIQUID ERC Is Now Available in the U.S.
GAMMAGARD LIQUID ERC (immune globulin infusion [human]) with less than or equal to 2 µg/mL IgA in a 10% solution, by prescription, is now available in the U.S.
Novartis’ Ianalumab Granted FDA Breakthrough Therapy Designation for Sjögren’s Disease
The U.S. Food and Drug Administration has granted breakthrough therapy designation to ianalumab for Sjögren’s disease.
Scientists Develop Inhalabale Nanotherapy to Fight Melanoma Resistant to Checkpoint Inhibitors
Researchers have developed an inhalable nanotherapy called BEAT (Bispecific Exosome Activator of T Cells) that can activate the immune system against cancers resistant to current checkpoint inhibitor therapies.
Human Trials Begin for Fentanyl Vaccine to Prevent Overdoses
A vaccine that blocks the effects of fentanyl, including overdoses, is scheduled for Phase I human trials in the Netherlands in early 2026 to assess its safety.
HHS Doubles AI-Backed Cancer Research Funding
The U.S. Department of Health and Human Services has doubled funding for its Childhood Cancer Data Initiative at the National Institutes of Health
NIH Launches $50 Million Autism Data Science Initiative
The National Institutes of Health launched the $50 Million Autism Data Science Initiative, supporting 13 pioneering projects
$3.4 Million Grant Awarded to Study Treatments for CCHFV
The National Institutes of Health granted Scott Pegan, PhD, nearly $3.4 million to lead an study to develop protective antibodies against Crimean Congo hemorrhagic fever virus
NIH Grant Awarded to Study Treatment for Crohn’s Disease
Trethera Corp., a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, has been awarded a $1.8 million National Institutes of Health (NIH) grant for preclinical studies of TRE515 as a Crohn’s disease treatment. TRE515 is a once-daily oral therapy that inhibits deoxycytidine kinase (dCK), an enzyme critical to the deoxyribonucleoside salvage […]
Study Shows No Causal Relationship Between COVID-19 Vaccination and Myositis
According to a study that analyzed the Veteran’s Health Administration records found there is no evidence to suggest COVID-19 vaccination increases the risk of developing idiopathic inflammatory myositis.